<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060203</url>
  </required_header>
  <id_info>
    <org_study_id>PHAR1A02</org_study_id>
    <secondary_id>CWRU-PHAR-1A02</secondary_id>
    <secondary_id>PHARMACIA-196-ONC-0100-006</secondary_id>
    <nct_id>NCT00060203</nct_id>
  </id_info>
  <brief_title>Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I/II Study of the Safety and Efficacy of Brostallicin (PNU-166196A) in Adult Patients With Multiple Myeloma That Has Progressed on Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who&#xD;
      have recurrent or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective tumor response rate (confirmed complete response and confirmed&#xD;
           partial response) of brostallicin in patients with recurrent or refractory multiple&#xD;
           myeloma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Determine the time to and duration of response, time to treatment failure, time to tumor&#xD;
           progression, and survival in patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Correlate baseline whole blood levels and activity of glutathione with clinical outcome&#xD;
           in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study.&#xD;
&#xD;
        -  Phase I: Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat&#xD;
           every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Additional patients are accrued and treated at the MTD of brostallicin as in&#xD;
           phase I.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-52 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>â€¢ Determine the objective tumor response rate (confirmed complete response and confirmed partial response) of brostallicin in patients with recurrent or refractory multiple myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose of brostallicin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Brostallicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brostallicin</intervention_name>
    <description>Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.</description>
    <arm_group_label>Brostallicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of multiple myeloma based on prior or current demonstration of the&#xD;
             following criteria*:&#xD;
&#xD;
               -  Major criteria:&#xD;
&#xD;
                    -  Plasmacytoma on tissue biopsy&#xD;
&#xD;
                    -  Bone marrow plasmacytosis with at least 30% plasma cells&#xD;
&#xD;
                    -  Monoclonal globulin spike on serum electrophoresis exceeding 3.5 g/dL for&#xD;
                       IgG peaks or 2.0 g/dL for IgA peaks; greater than 1,000 mg/24hr of kappa or&#xD;
                       gamma light chain excretion on urine electrophoresis in the absence of&#xD;
                       amyloidosis&#xD;
&#xD;
               -  Minor criteria:&#xD;
&#xD;
                    -  Bone marrow plasmacytosis with 10% to 30% plasma cells&#xD;
&#xD;
                    -  Monoclonal globulin spike present but less than levels in major criterion&#xD;
                       III above&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
                    -  Residual normal immunoglobulin M (IgM) no greater than 0.5 g/dL, IgA no&#xD;
                       greater than 0.1 g/dL, or IgG no greater than 0.6 g/dL NOTE: *Diagnosis of&#xD;
                       multiple myeloma requires a minimum of 1 major and 1 minor criterion (I and&#xD;
                       a together is not sufficient; must be I and b, I and c, I and d; II and b,&#xD;
                       II and c, II and d; III and a, III and c, III and d) or 3 minor criteria&#xD;
                       that must include a and b (a, b, and c; a, b, and d)&#xD;
&#xD;
          -  Measurable disease defined by 1 of the following values:&#xD;
&#xD;
               -  Serum myeloma (M) protein (IgG or IgA) level greater than 1.0 g/dL&#xD;
&#xD;
               -  Urine M protein (light chain disease) at least 300 mg/24hr&#xD;
&#xD;
               -  Soft tissue plasmacytoma with bidimensional measurement at least 20 x 20 mm (10 x&#xD;
                  10 mm if spiral CT scan is used)&#xD;
&#xD;
          -  Must have progressed during or within 12 months of discontinuing prior&#xD;
             myelosuppressive chemotherapy (e.g., vincristine, doxorubicin, and dexamethasone (VAD)&#xD;
             or melphalan) OR not responded after 2 courses of prior myelosuppressive chemotherapy&#xD;
&#xD;
          -  No indolent or smoldering myeloma or localized plasmacytoma&#xD;
&#xD;
          -  No known brain or leptomeningeal disease unless such lesions were previously&#xD;
             irradiated, are currently not being treated with corticosteroids, and are associated&#xD;
             with no clinical symptoms&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3 (at least 1,000/mm^3 if neutropenia due&#xD;
             to replacement of the normal bone marrow cells by myeloma cells)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (at least 50,000/mm^3 if thrombocytopenia due to&#xD;
             replacement of the normal bone marrow cells by myeloma cells)&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (no transfusion allowed)&#xD;
&#xD;
          -  No hyperviscosity syndrome&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum glutamate oxaloacetate transaminase (SGOT) no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 3.0 times ULN&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and sampling for study analysis&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No active infectious process or other severe concurrent disease that would make the&#xD;
             patient inappropriate for study entry&#xD;
&#xD;
          -  No mental incapacity or psychiatric illness that would preclude giving informed&#xD;
             consent or completing follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer biological response modifiers&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 years since prior high-dose chemotherapy with autologous bone marrow&#xD;
             transplantation or stem cell support&#xD;
&#xD;
          -  More than 4 weeks since prior myelosuppressive chemotherapy&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  No concurrent chronic steroids&#xD;
&#xD;
               -  Acute pulse dosing required for treatment of a concurrent medical condition is&#xD;
                  allowed, provided treatment duration is no greater than 2 weeks&#xD;
&#xD;
          -  No concurrent corticosteroids (e.g., dexamethasone)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 14 days since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No plans for radiotherapy within the next 6 months&#xD;
&#xD;
          -  Concurrent palliative radiotherapy for skeletal pain allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 14 days since prior surgery&#xD;
&#xD;
          -  No plans for surgery within the next 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Acute toxic effects of prior therapy (except for alopecia and neurotoxicity) must have&#xD;
             resolved to grade 0, 1, or the patient's baseline&#xD;
&#xD;
               -  Treatment-related neurotoxicity must have resolved to the patient's baseline, not&#xD;
                  to exceed grade 2&#xD;
&#xD;
          -  Chronic bisphosphonates for bone pain allowed only for maintenance doses&#xD;
&#xD;
          -  More than 2 weeks since prior nonmyelosuppressive antimyeloma therapy&#xD;
&#xD;
          -  More than 2 weeks since prior macrolide antibiotics&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent macrolide antibiotics&#xD;
&#xD;
          -  No concurrent participation in another treatment clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillard M. Lazarus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

